Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. LindahlBusiness Wire · Oct 16, 2026
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?Zacks Investment Research · Oct 6, 2026
Russian plague outbreak could boost these under-the-radar pharma stocksInvezz · Oct 5, 2026
Emergent Biosolutions (NYSE:EBS) Stock: Insider Paul Anthony Williams Sells 3,000 SharesDefense World · Oct 5, 2026
Emergent Biosolutions Inc. (NYSE:EBS) Stock Has Consensus Price Target of $10.00Defense World · Oct 5, 2026
Contrasting Emergent Biosolutions (NYSE:EBS) and Coherus Oncology (NASDAQ:CHRS)Defense World · Sep 28, 2026Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.09 | $0.60 | Beat |
| Apr 30, 2026 | -$0.25 | $0.21 | Beat |
| Feb 26, 2026 | $0.11 | -$0.43 | Miss |
| Oct 29, 2025 | -$0.12 | $1.06 | Beat |
| Aug 6, 2025 | -$0.26 | $0.16 | Beat |
| May 7, 2025 | $0.49 | $0.71 | Beat |